Source comparison
Tesamorelin + Ipamorelin: Dosing Protocol Comparison
Standard Research Protocol 2mg daily 200–300mcg daily Once daily (evening) Visceral fat reduction, general anti-aging 8–12 weeks for VAT loss, 12–16 weeks for skin quality Gold standard for clinical trials. Dosing aligns with published efficacy data Conservati
This comparison does not assign a generated winner or score.
- Standard Research Protocol
- 2mg daily
- 200–300mcg daily
- Once daily (evening)
- Visceral fat reduction, general anti-aging
- 8–12 weeks for VAT loss, 12–16 weeks for skin quality
- Gold standard for clinical trials. Dosing aligns with published efficacy data
- Conservative Low-Dose
- 1mg daily
- 100–200mcg daily
- Minimal effective dose, reduced side effect risk
- 12–16 weeks for VAT loss, 16–20 weeks for visible skin changes
- Appropriate for first-time users or those with GH sensitivity concerns. Slower onset but improved tolerability
- Pulsed High-Dose (5 days on / 2 days off)
- 300–500mcg daily
- Five consecutive days per week
- Maximized GH peaks, receptor sensitivity preservation
- 8–10 weeks for VAT loss, accelerated collagen synthesis
- Used in advanced protocols to prevent tachyphylaxis. Requires careful cycle management
- Split-Dose Protocol
- 1mg twice daily
- 150mcg twice daily
- Morning + evening
- Sustained GH elevation, mimicking natural pulsatile rhythm
- 10–14 weeks for VAT loss, comparable skin quality timeline
- Theoretically superior but logistically complex. Minimal evidence of superiority over single daily dosing
- Tesamorelin's half-life is 26–38 minutes, ipamorelin's is approximately 2 hours. Both are cleared rapidly, meaning timing consistency matters more than total daily dose for maintaining stable GH secretion patterns. Evening dosing (60–90 minutes before bed) aligns with the endogenous nocturnal GH pulse and maximizes sleep-related benefits.